Neuberger Berman Group LLC Bio Atla, Inc. Transaction History
Neuberger Berman Group LLC
- $124 Billion
- Q2 2025
Shares
2 transactions
Others Institutions Holding BCAB
# of Institutions
42Shares Held
13.7MCall Options Held
20.7KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.84MShares$3.19 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$1.28 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.49MShares$985,0840.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$906,8900.03% of portfolio
-
Black Rock Inc. New York, NY792KShares$522,4290.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $24M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...